Medical/Pharmaceuticals

Korea Innovation Foundation selects 2 Innovative bio health companies, LEEBIO, and Airlab for Global Technology Commercialization Support Program (North America)

DAEJEON, South Korea, Nov. 26, 2025 /PRNewswire/ -- Korea Innovation Foundation (INNOPOLIS), currently operating the 2025 Global Technology Commercialization Support Program (North America), announces that 2 innovative companies, LEEBIO, and Airlab are chosen for the support program. This initia...

2025-11-26 13:45 1741

BON Announced Next-Gen of Tea Pigment Digestive Health Products and Cooperation Agreement of US$26 Million with Beijing Huahai Keyuan

XI'AN, China, Nov. 25, 2025 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, today announced a non-exclusive cooperation agreement with Beijing Huahai Keyuan Technology Co...

2025-11-25 22:41 3696

Mabwell Announces First-Patient Dosing for Novel CDH17-Targeting ADC 7MW4911

SHANGHAI, Nov. 25, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the first patient has been dosed in the Phase I/II clinical trial of its independently developed novel CDH17-targeting antibody-drug ...

2025-11-25 22:00 3417

Neurophet and The Florey Strengthen Research Collaboration on 'Neurophet AQUA' to Advance Alzheimer's Disease Diagnosis

* Aiming to evaluate the utility of blood-based and other biomarkers for Alzheimer's disease diagnosis and management * Joint research to enhance dementia diagnosis using the brain neurodegeneration imaging software 'Neurophet AQUA' SEOUL, South Korea, Nov. 25, 2025 /PRNewswire/ -- Neurophet ...

2025-11-25 22:00 3632

Mazdutide 9mg Supplementary Application Accepted for Review by China's NMPA, Potentially Offering a Novel Drug Option for Moderate-to-Severe Obese Population

SAN FRANCISCO and SUZHOU, China, Nov. 25, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metaboli...

2025-11-25 17:00 2584

HKeyBio Launches the HKEY-AIDMD 3.0--a Next-Generation Platform to Crack the Toughest Challenge in Autoimmune and Allergy Drug Development: Multi-target Combination Strategy Optimization

* The newly upgraded HKEY-AIDMD 3.0 model library features nearly 300 autoimmune and allergy-related disease models. For multiple major indications, HKeyBio has established four-dimensional (4D) model pools that simulate clinical heterogeneity, providing a mechanism-driven model selection platf...

2025-11-25 00:30 2949

ToolGen and GenEditBio Enter Strategic Cross-License Agreement to Accelerate Development of Innovative Genome-Editing Therapeutics

* Integrates ToolGen's best-in-class CRISPR-Cas9 platform with GenEditBio's industry-leading lipid nanoparticle (LNP) delivery technology * Pursues a "once-and-done" treatment paradigm for diseases with high unmet medical needs SEOUL, South Korea, Nov. 24, 2025 /PRNewswire/ -- ToolGen Inc. (K...

2025-11-24 22:00 2460

HoneyNaps Accelerates Clinical Trial Pipelines with FDA-Cleared AI "SOMNUM"

* Enhancing Clinical Efficiency with AI Sleep Analysis: Cutting Both Cost and Time * Joint Clinical Studies with CROs: SOMNUM™ AI Sleep Scoring Drives Higher Efficiency * FDA-cleared AI solution shortens clinical trial timelines while ensuring data reliability * Expanded global partnershi...

2025-11-24 17:24 1503

Pin Therapeutics Initiates First-Patient Dosing of CK1α Degrader PIN-5018 in Phase 1 Trial

Preclinical Results Demonstrate Complete Response and Tumor Regression in ACC PDX Models SEOUL, South Korea, Nov. 24, 2025 /PRNewswire/ -- Pin Therapeutics, a clinical-stage biotechnology company specializing in targeted protein degradation, announced onNovember 20 that it has administered the f...

2025-11-24 15:11 1876

Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 23, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics for immunology and oncology, today announced an u...

2025-11-24 08:01 2673

Exploring the Next Era of CGT and Unlocking Limitless Possibilities: The GenScript Biotech Global Forum London 2025 Wraps Up

PISCATAWAY, N.J., Nov. 21, 2025 /PRNewswire/ -- GenScript Biotech Corporation, a global leader in life sciences R&D and manufacturing services, successfully hosted the GenScript Biotech Global Forum London 2025 in the UK. This marks the Forum's second edition inEurope and the eighth consecutive G...

2025-11-22 06:32 3166

BioDlink and Lepu Biopharma Celebrate Successful Launch of the World's First EGFR-Targeting ADC Drug, Marking a Major Milestone in Mutual Collaboration in Biologics CMC

* Celebrating a Shared Milestone: BioDlink and Lepu Biopharma celebrated the launch of MEIYOUHENG®, the world's first EGFR-Targeting ADC, and their partnership spanning over two years. * Demonstrating Robust Capabilities: Throughout the collaboration, all technology transfers and GMP manufact...

2025-11-21 21:00 4137

Dimora Medical Reaffirms Long-Term Commitment to Pressure Injury Patients on Worldwide Pressure Injury Prevention Day

NEW YORK, Nov. 20, 2025 /PRNewswire/ -- Observed annually on the third Thursday of November each year, Worldwide Pressure Injury Prevention Day serves as a global reminder of the urgent need to prevent pressure injuries, also known as pressure ulcers or bedsores, among vulnerable populations. Est...

2025-11-21 11:14 4229

HitGen Receives New Funding to Discover Novel Therapeutics for Underserved Diseases

* Company enters into new agreement with the Gates Foundation to identify novel drug leads targeting tuberculosis and malaria and new agents for non-hormonal contraception. CHENGDU, China, Nov. 20, 2025 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH...

2025-11-20 22:30 2660

ReviR Therapeutics Receives $4.6 Million CIRM Grant to Advance Huntington's Disease Treatment and Announces Key Development Milestone

BRISBANE, Calif., Nov. 20, 2025 /PRNewswire/ -- ReviR Therapeutics, a biotech company focused on developing innovative treatments for neurogenetic diseases, announced today that it has been awarded a$4.6M grant from the California Institute for Regenerative Medicine (CIRM)

2025-11-20 22:00 3011

GENPRIME ACCELERATES GLOBAL GROWTH WITH FERTILITY CENTRE LAUNCHES IN SINGAPORE AND MANILA

The Singapore and New York-headquartered network of clinics expands its Southeast Asia presence, addressing global family-building challenges with technology and empathy NEW YORK, Nov. 20, 2025 /PRNewswire/ -- Rhea Fertility, the reproductive health platform headquartered inSingapore and New Yor...

2025-11-20 22:00 2094

Lunit and Labcorp Announce Strategic Collaboration to Advance AI-Powered Digital Pathology Research

DURHAM, N.C. and SEOUL, South Korea, Nov. 20, 2025 /PRNewswire/ -- Lunit, a leading provider of AI for cancer diagnostics and precision oncology, and Labcorp, a global leader of innovative and comprehensive laboratory services, today announced a collaborative initiative to accelerate innovation i...

2025-11-20 13:01 4477

Dimora Medical Supports HS Connect Empower Workshop to Promote Science-Based Care for Hidradenitis Suppurativa Patients

NEW YORK, Nov. 19, 2025 /PRNewswire/ -- Patient-centered nonprofit organization HS Connect recently hosted the Empower HS: Knowledge and Advocacy Workshop, an educational event designed to help individuals living with Hidradenitis Suppurativa (HS) and their caregivers gain the knowledge and confi...

2025-11-20 01:48 3456

Accelerating Drug Discovery: Tsingke Biotech Unveils Next-Generation Rapid Protein and Antibody Solutions

BEIJING and LISBON, Portugal, Nov. 19, 2025 /PRNewswire/ -- At PEGS Europe 2025, one of the industry's premier gatherings for innovation in protein and antibody engineering, Tsingke Biotech highlighted its latest acceleratedprotein and anti...

2025-11-19 22:17 3662

Nona Biosciences and Pfizer Announce Strategic Research Collaboration to Accelerate Antibody Discovery

Agreement includes license to Nona's fully human HCAb platform for preclinical antibody discovery CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions for biological drug discovery and development from I to I® (Idea to IN...

2025-11-19 20:08 2282
1 ... 47484950515253 ... 263

Week's Top Stories